
Keywords: AED; antiepileptic drug; MA; market authorization; ADR; adverse drug reactions; DEE; developmental and epileptic encephalopathy; PGenetic; pharmacoresponsive genetic epilepsies; Struct./met.; structural-metabolic etiologies confirmed or suspected; Antie